Tafalgie therapeutics team’s

Around its management team and founding partners, Tafalgie Therapeutics gathers a Scientific Committee and a Supervisory Board, but also federates a support team and a group of partners, all mobilized for the success of the project.

5 Founders

Tafalgie Therapeutics was set up by an experienced and dynamic team with complementary scientific and business experiences.

Eric Schettini

President

Stephane Gaillard

General Manager

Aziz Moqrich

Chief Scientific Officer

Olivier Blin

President of the
Executive Committee

Laurent Labatut

Chairman on the board

The Scientific Committee

The Scientific Committee, chaired by Aziz Moqrich, is a collegial advisory body and does not constitute a management body. Its mission is to advise the Chairman and other senior managers of the company in defining and implementing the company’s strategic orientations, to ensure the quality, legitimacy and consistency of its research and development activities and to monitor developments in science.

John Levine

Neuroscientist

Jon David Levine is an American neuroscientist known for his researches on pain and analgesia, particularly in the area of placebo studies. He is a professor of medicine, of oral and maxillofacial surgery, and of neurosciences at the University of California, San Francisco (UCSF).
 
Prof. Levine’s research focuses on pain and analgesia, such as the mechanism of the placebo effect in relieving pain. In 1978, he published an influential study showing that placebo analgesia could be blocked by the opioid antagonist naloxone.

Prof. Levine’s study represents the point where « placebo biology » was born.

Jean-Louis Kraus

Professor Emeritus at the University of Aix Marseille and former Professor at McGill University Montreal Canada

Jean-Louis Kraus is an emeritus professor at the University of Aix Marseille, france and a former Professor at the McGill University of Montreal Canada.
 
He has an extensive experience in the creation of biotechnology start-ups such as Trophos (which was acquired by Roche, Switzerland), BioPharmed and Planktovie. His international reputation in medicinal chemistry has led him to be a member of numerous scientific research evaluation committees (Inserm, FRM, Sidaction, ANRS) in France and abroad, as well as a senior scientist at Biochem Pharma (Canada. Moreover, he was a member of different advisory committees for strategic private investments and was in charge of the research & development at the Marseille University Council (Protisvalor creation).

Through his experience, Prof. Kraus has developed great networks during his career marked by commercial successes.

Alain Eschalier

Professor Emeritus at the University of Aix Marseille and former Professor at McGill University Montreal Canada

Alain Eschalier (MD, PhD, PharmD) is an emeritus professor of Medical Pharmacology at the University of Clermont Auvergne, France and is board certified in pharmacology, psychiatry and human biology.
 
He is also the former head of the medical pharmacology department of the Faculty of Medicine and the University Hospital of Clermont-Ferrand.
 
Moreover, he was the founding director of the Inserm research units on the fundamental and clinical pharmacology of pain, participated in the creation of two start-up companies and was a consultant for several companies.
 
He chairs the Analgesia Institute since 2014, as well as the biomedical and public health research committee (CRBSP) and the scientific council of the French Society of Pharmacology and Therapeutics (SFPT) since 2015.

Prof. Eschalier is developing his research on the preclinical and clinical pharmacology of analgesics and the pathophysiology of chronic pain.

» If the pain represents a crucial contemporary issue, the aging of the population only reinforces the need for curative solutions in this field. The personalities that compose the Tafalgie Therapeutics team appeared to me to be passionate, ambitious and solid! ”

Laurent Labatut – Chairman on the board